The investment firm has added the three companies to its US Life Science Tools & Diagnostics coverage while upping Hologic to an Equal Weight rating.
The letter informed the firm that its production of Xpert Norovirus assays at the Solna, Sweden site does not conform to good manufacturing practice requirements.
The Xpert Omni platform will launch in 2016 running Cepheid test cartridges on a compact battery-operated device that is anticipated to cost less than $3,000.
The firm saw 24 percent growth in commercial clinical reagents revenues, while clinical systems revenue was down 23 percent.
Bio-Reference Laboratories, Cepheid, Exact Sciences, and NanoString all saw their shares rise in June. Sequenom topped the list of decliners.
Deals with Quest and LabCorp and an expanded product offering also spurred the investment bank to increase its price target on Cepheid's stock to $75 per share from $52.
A study of more than 700 samples showed pooling detected 96 percent of the tuberculosis cases found via testing each patient sample individually, with 99 percent overall agreement between the methods.
Xpert Ebola joins three other tests on the World Health Organization's list of in vitro diagnostics eligible for procurement in Ebola-affected countries.
The firm is pursuing regulatory clearance for multiple tests and is targeting growth in an attractive CLIA market, a move that will require new hires.
The increased revenue was driven by growth in the firm's commercial clinical business.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.